| 159 | 2 | 31 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 :研究埃索美拉唑 (Eso)对胃内pH的影响是否与CYP2C19基因型有相关性。方法 :采用PCR RFLP方法对CYP2C19进行基因分型后 ,予Eso 4 0mg ,po ,qd ,连服 5d ,监测第 1,5次给药前 15min及给药后 2 4h胃内pH。结果 :2 7名志愿者分为 3种基因型 :10名纯合子快代谢型 (homEMs) ,14名杂合子快代谢型 (hetEMs)和 3名慢代谢型 (PMs)。在d 1和d 5 ,口服Eso 4 0mg后 2 4h胃内pH中位数平均值各基因型间无统计学差异 ,2 4h中胃内pH >4的时间百分比PMs和EMs之间有统计学差异 ,2 4h胃内pH >4的持续时间PMs比homEMs和hetEMs约长 2 0 % ,而homEMs和hetEMs之间无统计学差异。结论 :给予相同剂量Eso后 ,对EMs和PMs者的平均抑酸作用强度相似 ,但对PMs者作用持续时间比EMs长
Abstract：AIM: To examine whether the effect of esomeprazole (Eso) on intragastric pH depends on CYP2C19 genotype status. METHODS: CYP2C19 genotype status for 2 mutations associated with the poor metabolizer phenotype was determined by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 27 healthy Chinese volunteers. After 5 days' administration of Eso 40 mg, po, qd, intragastric pH values were monitored for 24 h on both d 1 and d 5 of the study period. RESULTS: The 27 subjects were divided into 3 genotype groups including 10 homozygous extensive metabolisers (homEMs), 14 heterozygous extensive metabolisers (hetEMs) and 3 poor metabolisers (PMs) according to PCR-RFLP analysis. Oral administration of either a single dose of Eso 40 mg or repeated doses of Eso 40 mg once daily for 5 d did not produce statistically significant difference in the mean 24 h median pH values among the 3 genotype groups. With respect to the percentage of 24-hour monitoring period with pH>4, PMs showed about 20% longer duration of effect than homEMs and hetEMs on both d 1 and d 5 after dosing (P<0.05), while hetEMs was not significantly different from homEMs. CONCLUSION: The acid inhibitory effect of Eso is similar in potency among the subjects with different CYP2C19 genotypes, though different in duration between EMs and PMs.
[1]AnderssonT ,BredbergE ,SunzelM ,etal.Pharmocokinetics(PK)andeffectonpentagastrinstimulatedpeakacidoutput(PAO)ofomepra zole(O)andits2opticalisomers,S omeprazole/Esomeprazole(E)andR omeprazole(R O)[J].Gastroenterology,2000,118(4):A1210.
[2]AnderssonT .Pharmacokinetics,metabolism,andinteractionsofacidpumpinhibitors.Focusonomeprazole,lansoprazoleandpantoprazole[J].ClinPharmacokinet,1996,31(1):9.
[3]FurutaT ,OhashiK ,KosugeK ,etal.CYP2C19genotypestatusandeffectofomeprazoleonintragastricpHinhumans[J].ClinPharmacolTher,1999,65(5):552.
[4]NogueraNI,TallanoCE ,BragosIM ,etal.Modifiedsalting outmethodforDNAisolationfromnewborncordbloodnucleatedcells[J].JClinLabAnal,2000,14(6):280.
[5]deMoraisSMF ,WilkinsonsGR ,BlaisdellJ,etal.ThemajorgeneticdefectresponsibleforthepolymorphismofS mephenytoinmetabolisminhumans[J].JBiolChem,1994,269(22):15419.
[6]KubotaT ,ChibaK ,IshizakiT .GenotyingofS mephenytoin4’ hydrox ylationinanextendedJapanesepopulation[J].ClinPharmacolTher,1996,60(6):661.
[7]KubotaT ,HibiN ,ChibaK .LinkageofmutantallelesofCYP2C18andCYP2C19inanJapanesepopulation[J].BiochemPharmacol,1998,55(12):2039.
[8]deMoraisSMF ,WilkinsonsGR ,BlaisdellJ,etal.Identificationofanewgeneticdefectresponsibleforthepolymorphismof(S) mephenytoinmetabolisminJapanese[J].MolPharmacol,1994,46(4):594.
[9]BalianJD ,SukhovaN ,HarrisJW ,etal.Thehydroxylationofomepra zolecorrelateswithS mephenytoinmetabolism:apopulationstudy[J].ClinPharmacolTher,1995,57(6):662.
[10]KatashimaM ,YamamotoK ,TokumaY ,etal.Comparativepharma cokinetic/pharmacodynamicanalysisofprotonpumpinhibitorsomepra zole,lansoprazoleandpantoprazole,inhumans[J].EurJDrugMetabPharmacokinet,1998,23(1):19.
[11]HuangJQ ,HuntRH .pH ,healingrate,andsymptomreliefinpatientswithGERD .YaleJBiolMed,1999,72(23):181.
[12]AnderssonT .HassanAlinM .HasselgrenG .etal.Pharmacokineticstudieswithesomeprazole,the(S) isomerofomeprazole[J].ClinPharmacokinet,2001,40(6):411.
基本信息:
DOI：10.19577/j.cnki.issn10074406.2004.03.001
中图分类号:R96
引用信息:
[1]仲珑瑾,程能能,李兆申,陈斌艳,王永铭.埃索美拉唑对不同CYP2C19基因型中国人健康志愿者胃内pH的影响(英文)[J].中国临床药学杂志,2004(03):129-132.DOI:10.19577/j.cnki.issn10074406.2004.03.001.
2004-05-25
2004-05-25